New BET therapies could help beat resistance in solid cancers
New research into BET protein inhibitors suggests that next-generation therapies may overcome previous clinical limitations such as drug resistance and side effects in solid tumor treatments. By targeting proteins like BRD4, scientists aim to improve the efficacy of cancer treatments that previously struggled in clinical trials.
Why it matters
Advancements in targeted cancer therapies are critical for improving patient outcomes in cases where traditional treatments have failed due to drug resistance.
New research suggests that the next generation of therapies targeting BET proteins could overcome the limitations of earlier drugs and improve treatment options for patients with a range of solid tumours .
The research examines the current landscape of BET-targeted therapies highlights how advances in drug design and combination treatments are renewing optimism for a strategy that initially showed promise but struggled to deliver consistent clinical benefits.
BET proteins, particularly BRD4, play a central role in driving cancer growth by regulating the expression of genes linked to tumour development. While first-generation BET inhibitors demonstrated encouraging results in laboratory studies, their success in clinical trials was limited by modest effectiveness, significant side effects and the development of drug resistance.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in